Telpres Plus tablets are used for arterial hypertension. As a combination with a fixed dose, Telpres Plus is used when telmisartan monotherapy does not provide adequate blood pressure control.
The active substance is telmisartan and hydrochlorothiazide.
1 tablet contains telmisartan 40 mg and hydrochlorothiazide 12.5 mg telmisartan 80 mg and hydrochlorothiazide 12.5 mg, telmisartan 80 mg and hydrochlorothiazide 25 mg.
Excipients: mannitol (E 421), povidone, crospovidone, meglumine, sodium hydroxide, lactose, microcrystalline cellulose, hypromellose, sodium starch (type A), magnesium stearate, yellow iron oxide (E 172).
Telpres is taken once a day with a sufficient amount of liquid, regardless of food intake.
Pregnancy
The preparation is contraindicated for use in pregnant women or women planning pregnancy. If pregnancy is confirmed during treatment with this preparation, its use must be stopped immediately and, if necessary, replaced with another preparation approved for use by pregnant women.
Children
Telmisartan is not recommended for use in children (under the age of 18) due to the lack of sufficient data on the safety and efficacy of the preparation.
Drivers
With antihypertensive therapy, including telmisartan, when driving vehicles or other mechanisms, it is necessary to take into account the possibility of dizziness or hypersomnia.
Information on overdose of telmisartan in humans is limited. The level of withdrawal of hydrochlorothiazide by hemodialysis has not been established.
With an overdose of telmisartan, the most pronounced manifestations were arterial hypotension and tachycardia, bradycardia, dizziness, vomiting, increased serum creatinine levels and acute renal failure were also reported. An overdose of hydrochlorothiazide is associated with a decrease in the concentration of electrolytes (hypokalemia, hypochloremia) and hypovolemia due to excessive diuresis. The most common symptoms of an overdose are nausea and drowsiness. Hypokalemia can lead to muscle spasm and / or exacerbation of cardiac arrhythmias with concomitant use of digitalis glycosides or certain antiarrhythmic preparations.
Serious adverse reactions, including anaphylactic reactions and angioedema, are rare (≥ 1/10 000 to <1/1000), and acute renal failure is also observed.
The combination of telmisartan and aliskiren is contraindicated in patients with diabetes mellitus and impaired renal function (GFR <60 ml / min / 1.73 m2).
Store in its original packaging at a temperature not exceeding 25 ° C, out of the reach of children.
Shelf life is 3 years.
There are no reviews for this product.